Schreiner MediPharm’s High-Tech Digital Adherence Monitoring Solution Wins FINAT Award

Smart Blister Card enables real-time tracking of medication intake and patient adherence

Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, won a prestigious award for its Smart Blister Card from the European Association of the Self-Adhesive Label Industry (FINAT), which recognizes the industry’s best products. The Smart Blister Card, which extends standard multi-dose blister packs by a digital adherence monitoring tool enabling tracking of medication intake in real time, received the top honor in the “Innovation & Electronic Printing – Electronic Devices” category.

In the case of polypharmaceutical applications (permanent therapies involving the simultaneous prescription of several medications), pills are frequently filled into standard blister packs by hospital and large pharmacies so that patients can take them according to their medication plans. However, physicians and pharmacies typically have no way of tracking whether and when patients have taken their medicines. Schreiner MediPharm’s Smart Blister Card tackles this challenge by enabling digital medication adherence monitoring.

Integrated into the Smart Blister Card are conductive lines combined with an electronic unit. Once the patient pushes a tablet out of a cavity, data is generated in real time and includes information such as the exact time of pill removal, the respective cavity, and the dose it contains. The data is then stored in the Smart Blister Card and transmitted to a database via a smartphone app or a reader using NFC or Bluetooth technology.

For physicians and pharmacists, the handling of the Smart Blister Card is both convenient and flexible. After filling and sealing the blister pack, the Smart Blister Card is simply attached to the back of the pack without impairing the filling process. The technology can be inconspicuously integrated into the packaging design, and the marking of each cavity remains clearly visible. In addition, a temperature monitoring feature for sensitive ingredients is an available option.

The Smart Blister Card is suitable for nearly all existing multi-dose and single-dose blister packs. Patients can take their pills as usual because the cavities can be pushed through as easily as before. Additionally, smartphone apps can provide patients with digital self-monitoring support and even enable a reminder function to comply with their medication plan. Thus, Schreiner MediPharm’s Smart Blister Card helps enhance therapeutic success in polypharmaceutical applications.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.